Import 3-Chloro-4-Fluoroaniline — Buy in wholesale FOB from Supplier in China

3-chloro-4-fluoroaniline (CAS 367-21-5) is a halogenated aromatic amine with molecular formula C6H5ClFN and molecular weight 145.56 g/mol, possessing a fluorine at the 4-position and chlorine at the 3-position on the aniline nucleus. This substitution pattern confers unique electronic properties, with the fluorine's strong electronegativity and small atomic radius enabling specific reactivity profiles in nucleophilic aromatic substitution and metal-catalysed coupling reactions. Nanjing Chuanghua Biopharm Company Limited supplies this compound from their facility in Nanjing, Jiangsu Province, with the listing indicating a purity level above 98% as standard. The biopharm designation in the company name suggests intended or actual application in active pharmaceutical ingredient synthesis, though buyers should independently confirm GMP compliance status for their specific use case.

The compound is manufactured through reduction of the corresponding nitro precursor, typically via catalytic hydrogenation using palladium on carbon or iron-acid reduction, with fluorine substitution requiring controlled conditions to prevent defluorination. Purification relies on fractional distillation under reduced pressure or crystallisation from hydrocarbon solvents, with the 98% purity threshold representing standard commercial grade rather than pharmaceutical-grade material. For fluorinated anilines, residual fluoride ion content and hydrofluoric acid potential from decomposition are atypical concerns not present in chlorinated-only analogues, warranting specific analytical attention. The ortho relationship between chlorine and the amino group, para to fluorine, creates a steric and electronic environment favourable for palladium-catalysed Buchwald-Hartwig aminations and subsequent heterocycle formation in drug molecule construction.

Primary demand originates from pharmaceutical contract research organisations and generic API manufacturers synthesising fluoroquinolone antibiotics, antiviral compounds, and kinase inhibitors where the 3-chloro-4-fluoroanilino fragment appears in established molecules. Agrochemical applications include intermediates for fungicides and insecticides exploiting the fluorine's metabolic stability. Buyers in these sectors require material with documented batch-specific analytical data, stable isotopic composition for fluorine if relevant to regulatory submissions, and supply chain transparency for pharmacovigilance purposes. Nanjing Chuanghua's location in Nanjing's biopharmaceutical cluster provides access to analytical infrastructure and regulatory familiarity, though direct assessment of their quality systems remains essential before qualification for commercial API production.

Nanjing Chuanghua Biopharm Company Limited is headquartered at Block C, No.9 Huida Road, Nanjing 210032, Jiangsu, China, placing it within the Nanjing Jiangning or Qixia district industrial zones associated with the city's pharmaceutical and fine chemical sectors. The supplier holds harbor trust tier status on the platform, with a recorded response rate of 0.00% and zero average response hours, indicating no historical inquiry response data is captured through this channel. The company name explicitly references biopharmaceutical orientation, which may imply focus on GMP intermediates, custom synthesis, or API precursor supply, though this specialisation is not independently verified in the available profile.

No manufacturing certifications, facility audit results, annual revenue figures, employee counts, or client references are disclosed in the source data. The distinction between manufacturing and trading operations is unstated, requiring buyer diligence to determine whether Nanjing Chuanghua produces 3-chloro-4-fluoroaniline in-house or sources from third-party manufacturers. Importers should request proof of facility registration with Chinese regulatory authorities, environmental compliance records for fluorinated chemical production, and quality agreements appropriate to their intended application. The zero response metric suggests either a new listing or passive platform presence; direct outreach through the provided Jiangsu address or industry channels is advisable to assess current operational capacity and communication reliability.